JPMorgan Chase CEO Jamie Dimon Signals Potential 20 Billion Acquisition We Are on the Lookout UK Startup BioOrbit Launches Drug Manufacturing to Space with SpaceX Targeting SelfInjected Cancer Therapies US Consumer Sentiment Remains Gloomy Amid Persistent Inflation Geopolitical Tensions and Trade Policy Uncertainty Alibaba Unveils NextGeneration Zhenwu AI Chip and New Large Language Model Canadian Oil and Gas Stocks Continue to Shape Global Energy Markets A Sector Analysis Genpact CEO Suggests AI Could Reduce IT Workload Potentially Slow Employment Growth MNKD Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Reaction BioLife Solutions Q1 2026 Earnings EPS Slightly Misses Estimates Stock Declines CME Q1 2026 Earnings EPS Slightly Misses Consensus as Shares Edge Higher Ocugen Inc OCGN Q1 2026 Earnings Wider Loss Misses Estimate as PreRevenue Biotech Focuses on Pipeline NWN Q1 2026 Earnings EPS Misses Estimates Amidst Rising Costs and Weather Headwinds Nexgen Energy Ltd NXE Q1 2026 Earnings Deep EPS Miss as PreRevenue Developer Advances Key Projects FS Specialty Lending Fund FSSL Gains 189 as Shares Approach Key Resistance at 1243 Dorman Products DORM Holds Ground Near 118 as Momentum Remains Tentative PCB Bancorp PCB Trading Flat at 2479 as Stock Consolidates Between Support and Resistance Amplitude Inc AMPL Finds Support Near 637 Eyes Resistance at 704 After 276 Gain Bath Body Works BBWI Rises Broadly Testing Key Resistance Levels PFIS Q1 2026 Earnings Earnings Miss Estimates Amid Challenging Environment FRMEP Q1 2026 Earnings Depositary Shares Deliver EPS Beat Driven by Solid Core Performance SOS Limited Q3 2018 Earnings Significant EPS Miss Highlights Operational Challenges AGNCP Q1 2026 Earnings Strong EPS Beat Signals Resilience in RateSensitive Preferred PureCycle Technologies Inc Unit PCTTU Q1 2026 Earnings NarrowerthanExpected Loss Amid PreRevenue Phase ONBPP Q1 2026 Earnings Slight EPS Miss Amid Stable Performance Global Stocks Trade Mixed as Investors Await Fresh Developments on Iran SMXT Q1 2026 Earnings Narrow Loss Highlights Cost Management Focus Cellectis CLLS Slides 127 as Biotech Struggles to Hold Above Key Support